Duygu Ozmadenci, PhD, grew up in a small town on the Black Sea region of Turkey, across the waters from Chernobyl. As a teenager, she read a book that told stories of generations of people living in Anatolia and the land that eventually became Turkey. The depictions of the geography and flora, the description of … Continued
(June 11, 2020) Letters of Intent (LOIs) for Ovarian Cancer Research Alliance’s 2021 scientific grant awards are now open for submission. LOIs are due by July 10, 2020. Accepting LOIs is step one of OCRA’s highly competitive grant process. After LOIs are received, they are reviewed by our Scientific Advisory Committee (SAC), an esteemed group … Continued
To speak with Kimberly Richardson is to feel an instant camaraderie with someone who exhibits both calm and conviction, thoughtfulness and frank talk. She has learned a lot in the past 20 years – running triathlons, running a nonprofit in Chicago focused on small business development, teaching urban sociology as an adjunct professor – and … Continued
First-of-its-kind clinical trial validates remote genetic counseling (New York) June 01, 2020 – Genetic testing for cancer risk can significantly improve the prevention or treatment of hereditary cancers, but studies have shown that people who might have a genetic risk often don’t get tested. A collaborative Stand Up To Cancer ‘Dream Team’ of researchers co-funded … Continued
If there’s one thing that working toward an end to ovarian cancer has taught us, it’s that life is precious. We value the life of every person in our ovarian cancer community, and celebrate its diversity and strength. But today we stand in solidarity with our ovarian cancer community–and communities all over this country–in saying … Continued
Those who have faced an ovarian or gynecologic cancer diagnosis have so much to offer to others going through a similar experience – be it support, tips or friendship. Inspired Advice is a blog series that tackles specific topics – from managing treatment-related nausea to intimacy post-diagnosis – and shares advice and reflections from our OCRA Inspire … Continued
In 2005, Denise Lobodinski’s sister Renee was diagnosed with ovarian cancer at the age of 47. That same year, their father was diagnosed with prostate cancer. But her father’s doctor told Denise’s mother, “Don’t worry about your husband. Worry about your daughter.” In fifteen years, Denise feels like very little has changed in terms of … Continued
Covid-19 has disrupted nearly every aspect of life as we know it, and navigating a diagnosis and treatment for ovarian cancer – already a game changer – has been impacted as well. We want to better understand from our community exactly how this pandemic is affecting access to, and decisions around, treatment and clinical trials … Continued
Scared. Overwhelmed. Exhausted. Befuddled. These are common words one might use to describe how we feel during this unprecedented time in history. But Dmitriy Zamarin, MD, PhD, adds “fascinated” to the list as he ponders the psychological and sociological implications of the Covid-19 pandemic. “This small amount of genetic material that has spread through the … Continued
We reached out to our grantees and Scientific Advisory Committee, many of whom are on the frontlines – working in hospitals, meeting with patients, seeing firsthand the impact of Covid-19. We wanted to hear their words and reflections. “What do you wish everyone understood right now?” we asked them. “And what gives you hope?” Here … Continued
The world works in ironic and sometimes painful ways Yvette Jives, a nurse and social worker in North Carolina, has spent a lifetime helping others. She developed a women’s health program at the community center where she worked for 15 years (after working for 14 years in a hospital), monitoring patients’ cervical and breast cancer … Continued
(May 4, 2020) On April 29th, the Food and Drug Administration approved niraparib (Zejula, GlaxoSmithKline) as a first-line maintenance treatment for advanced epithelial ovarian, fallopian tube, or primary peritoneal cancer, regardless of BRCA mutation status. Niraparib was first approved by the FDA for treatment of recurrent ovarian cancer in 2017. This most recent approval means … Continued
Get email updates about research news, action alerts, and ways to join the fight.
